American Association for Cancer Research
00085472can112023-sup-can_11-2023_f14_pdf_8_7mb.pdf (8.48 MB)

Supplementary Figures 1-14 from 5-Hydroxymethylcytosine Is Strongly Depleted in Human Cancers but Its Levels Do Not Correlate with IDH1 Mutations

Download (8.48 MB)
journal contribution
posted on 2023-03-30, 20:48 authored by Seung-Gi Jin, Yong Jiang, Runxiang Qiu, Tibor A. Rauch, Yinsheng Wang, Gabriele Schackert, Dietmar Krex, Qiang Lu, Gerd P. Pfeifer

PDF file - 8.9MB



The base 5-hydroxymethylcytosine (5hmC) was recently identified as an oxidation product of 5-methylcytosine in mammalian DNA. Here, using sensitive and quantitative methods to assess levels of 5-hydroxymethyl-2′-deoxycytidine (5hmdC) and 5-methyl-2′-deoxycytidine (5mdC) in genomic DNA, we investigated whether levels of 5hmC can distinguish normal tissue from tumor tissue. In squamous cell lung cancers, levels of 5hmdC were depleted substantially with up to 5-fold reduction compared with normal lung tissue. In brain tumors, 5hmdC showed an even more drastic reduction with levels up to more than 30-fold lower than in normal brain, but 5hmdC levels were independent of mutations in isocitrate dehydrogenase-1. Furthermore, immunohistochemical analysis indicated that 5hmC is remarkably depleted in many types of human cancer. Importantly, an inverse relationship between 5hmC levels and cell proliferation was observed with lack of 5hmC in proliferating cells. The data therefore suggest that 5hmdC is strongly depleted in human malignant tumors, a finding that adds another layer of complexity to the aberrant epigenome found in cancer tissue. In addition, a lack of 5hmC may become a useful biomarker for cancer diagnosis. Cancer Res; 71(24); 7360–5. ©2011 AACR.

Usage metrics

    Cancer Research



    Ref. manager